Originating 80–100 explorations per year and founding ProtoCos→NewCos→GrowthCos, as principal organization builder building bioplatforms with in-house discovery engines alongside in‑house drug advancement unit partnered featuring Pfizer alongside Novo Nordisk.
Ranked by shared stages, industries, geography, cheque size and investor type. 400 related investors in the directory.
Is dedicated to companies empowering informed, connected health consumers and building system-level resilience to improve outcomes, experiences, and lower healthcare costs. With a clear focus on healthcare innovation, the firm brings both capital and domain expertise.
Invests in rigorously technical enterprise entrepreneurs (infrastructure, analytics, AI/ML, developer tools, security) with very compact initial checks and repeated follow-on backing, plus think-tank-style technical essays founders utilize as reference.
Spearheaded by a former Google X founder, the firm brings a moonshot lab prototyping philosophy anchored in a structured Triad investment thesis encompassing deep technology, reimagined unit economics, and climate-positive outcomes. It stands out by offering hands-on prototyping assistance and reverse-engineering of unit-economics models for its portfolio.
A climate-focused agrifood fund evolved from corporate-backed to institutional VC, presenting founders rare food-policy and regulatory expertise through partner Sam Kass. Through targeted capital deployment, the fund plays an active role in the startup ecosystem.
Targets hard, capital‑intensive sustainability technologies other VCs avoid, bridging solutions from developed markets into China and developing countries (energy, food, health, environment) to build traction back into developed markets. Through targeted capital deployment, the fund plays an active role in the startup ecosystem.
Co-led by Facebook co-founder Eduardo Saverin, delivers B2B startup ventures structured access to BCG consultants and corporate clients and supports expand across the US and Asia. The firm continues to build its presence across the venture capital landscape.
